SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Recruiting
Observational Study
Metastatic Castration-Resistant Prostate Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Male
- Study type
- Observational
- Participants needed
- 60 (estimated)
- Sponsor
- University of Michigan Rogel Cancer Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* \* 177Lu-617 PSMA treatment scheduled for mCRPC
* Clinically stable as determined by the nuclear medicine clinicians
* Male
* ≥ 18 years of age
* Willing and able to provide informed consent
Exclusion Criteria:
* Patients who are unable to lie flat on the imaging sy…
Contacts
No contact information available.